<unk> , sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis.<unk>  was approved for medical use in Japan in September 2021, and in the United States in October 2021. It is the first orally-administered inhibitor of the complement C5a receptor approved by the U.S. Food and Drug Administration (FDA).
Avacopan
Bocasan
Buffalopox
Bethanechol
Tolperisone
Osilodrostat
Ioxilan
Iopromide